merger detail suggest primari bidder
def public file reveal parti includ least interest
partner strateg nite chm nsr-rpgr xlrp among
pipelin product ultim anoth compani convey interest
timelin event
prior nite ipo sep management hold preliminari discuss
two compani regard potenti strateg partnership focus primarili
in-licens choroideremia chm
june parti contact ceo david fellow conduct dilig
chm nsr-rpgr xlrp nite manufactur capabl parti later
show interest stargardt diseas well
juli cfo senthil sundaram meet vice-president daniel karp discuss
interest gene therapi
aug parti inform nite board member david mott interest
nite product portfolio fellow meet parti sept
oct nite report preliminari phase data xlrp compani meet
parti discuss strateg interest ophthalmolog gene therapi
sep-dec nite hold variou meet parti conduct due
dilig nite
parti show interest strateg transact
nite grant parti access electron data room nite meet
parti discuss valuat forecast parti confirm confirm prepar non-
dec parti offer non-bind propos premium
dec nite provid parti access electron data room
jan parti grant access data room
jan offer non-bind propos premium
feb grant access second electron data room
feb parti parti disclos plan pursu acquisit
time howev parti indic interest strateg collabor
feb parti indic plan pursu acquisit would instead
interest strateg partnership
feb nite send bid process letter
feb centerview note nite plan announc transact march
prior propos unattract
propos acquisit price premium
feb earli march parti parti enter activ discuss nite around
increas deal offer
biib propos acquisit nite announc
pleas see analyst certif import disclosur inform inform regard statu non-u analyst
page report
also nite manag revenu forecast includ peak sale
bull case peak sale base case
peak sale bear case
pleas see import disclosur inform page report
spun univers oxford januari nite develop pipelin proprietari gene-therapi product candid
treatment inherit retin diseas ird led ceo dr david fellow compani initi phase studi
investig lead drug treatment choroideremia chm believ advanc product
candid indic present addit compani develop gene therapi candid ird
includ nsr-rpgr xlrp best vitelliform macular dystrophi
pt base ep probability-adjust dcf risk includ pipelin disappointments/success
michael yee certifi view express research report accur reflect person view subject
secur subject compani also certifi part compens directli indirectli relat
specif recommend view express research report
andrew tsai certifi view express research report accur reflect person view subject
secur subject compani also certifi part compens directli indirectli relat
specif recommend view express research report
kelechi chiker ph certifi view express research report accur reflect person view
subject secur subject compani also certifi part compens directli indirectli
relat specif recommend view express research report
arshad haider certifi view express research report accur reflect person view subject
secur subject compani also certifi part compens directli indirectli relat
specif recommend view express research report
case jefferi employe analyst respons coverag financi instrument discuss
report receiv compens base part overal perform firm includ invest bank incom seek
updat research appropri variou regul may prevent us asid certain industri report publish
period basi larg major report publish irregular interv appropri analyst judgement
articl articl
jefferi llc act financi advisor nightstar therapeut plc announc acquisit biogen inc
jefferi group llc make market secur adr nightstar plc
jefferi group llc make market secur adr biogen inc
jefferi group llc affili subsidiari expect receiv intend seek compens invest bank servic
nightstar plc within next three month
within past twelv month nightstar therapeut plc client jefferi llc invest bank servic
provid
jefferi group llc affili subsidiari act manag co-manag underwrit placement secur
nightstar plc one affili within past twelv month
explan jefferi rate
buy describ secur expect provid total return price appreci plu yield within period
pleas see import disclosur inform page report
hold describ secur expect provid total return price appreci plu yield plu minu within
under-perform describ secur expect provid total return price appreci plu yield minu less within
expect total return price appreci plu yield buy rate secur averag secur price consist
within period compani typic volatil overal stock market hold rate
secur averag secur price consist expect total return price appreci plu yield plu minu
within period under-perform rate secur averag secur price consist expect
total return price appreci plu yield minu less within period
nr invest rate price target temporarili suspend suspens complianc applic
cs coverag suspend jefferi suspend coverag compani
nc cover jefferi cover compani
restrict describ issuer conjunct jefferi engag certain transact compani polici applic
secur regul prohibit certain type commun includ invest recommend
monitor describ secur whose compani fundament financi monitor financi project
opinion invest merit compani provid
jefferi methodolog assign rate may includ follow market capit matur growth/valu volatil
expect total return next month price target base sever methodolog may includ
restrict analys market risk growth rate revenu stream discount cash flow dcf ebitda ep cash flow cf free cash
price-to-earnings sum part net asset valu dividend return return equiti roe next month
jefferi franchis pick includ stock select among best stock idea equiti analyst month period
stock select base fundament analysi may take account factor analyst convict differenti
analysi favor risk/reward ratio invest theme jefferi analyst recommend jefferi franchis pick
includ buy rate stock number vari depend analyst recommend inclus stock ad
new opportun aris remov reason inclus chang stock met desir return longer rate
buy and/or trigger stop loss stock day volatil bottom quartil stock continu
stop loss remaind stop franchis pick intend repres recommend portfolio stock
sector base may note believ pick fall within invest style growth valu
risk may imped achiev price target
report prepar gener circul provid invest recommend specif individu investor
financi instrument discuss report may suitabl investor investor must make
invest decis base upon specif invest object financi situat util financi advisor
deem necessari past perform financi instrument recommend report taken indic
guarante futur result price valu incom financi instrument mention report rise well
fall may affect chang econom financi polit factor financi instrument denomin currenc
investor home currenc chang exchang rate may advers affect price valu incom deriv
financi instrument describ report addit investor secur adr whose valu affect
currenc underli secur effect assum currenc risk
compani mention report
pleas see import disclosur inform page report
rate price target histori nightstar therapeut plc nite
jefferi llc act financi advisor nightstar therapeut plc announc acquisit biogen inc
rate price target histori biogen inc
jefferi llc act financi advisor nightstar therapeut plc announc acquisit biogen inc
note box rate price target histori chart repres action past three year analyst
initi compani made chang rate price target compani discontinu coverag compani
distribut rate
distribut rate
pleas see import disclosur inform page report
